Spots Global Cancer Trial Database for papillary thyroid cancer
Every month we try and update this database with for papillary thyroid cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging | NCT03470259 | Papillary Thyro... Lymph Node Meta... | IV adminstratio... Multispectral F... Spectroscopy | 18 Years - | University Medical Center Groningen | |
| A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | NCT04731467 | Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden... | CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N... | 18 Years - | Purple Biotech Ltd. | |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | NCT04544111 | Thyroid Cancer Thyroid Cancer,... Papillary Thyro... Follicular Thyr... Hurthle Cell Tu... Poorly Differen... Hurthle Cell Th... | Trametinib Dabrafenib PDR001 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | NCT05024929 | Papillary Thyro... Pediatric Cance... Differentiated ... | Whole body scan | 0 Years - | Children's Hospital of Philadelphia | |
| Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma | NCT04664413 | Papillary Thyro... | 18 Years - | University of Salerno | ||
| Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer | NCT04948437 | Thyroid Cancer Papillary Thyro... Follicular Thyr... | 20 Years - 80 Years | National Taiwan University Hospital | ||
| Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer | NCT04624477 | Papillary Thyro... Papillary Thyro... Papillary Micro... | 18 Years - | University Health Network, Toronto | ||
| Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation | NCT04129411 | Papillary Thyro... Papillary Thyro... | RFA | 18 Years - 85 Years | Mayo Clinic | |
| A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. | NCT03469011 | Papillary Thyro... | Imatinib Oral T... | 18 Years - | AHS Cancer Control Alberta | |
| Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer | NCT03271892 | Thyroid Cancer ... | 18 Years - 100 Years | University Health Network, Toronto | ||
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer | NCT00121628 | Thyroid Cancer | AMG 706 | 18 Years - | Amgen | |
| Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer | NCT03271892 | Thyroid Cancer ... | 18 Years - 100 Years | University Health Network, Toronto | ||
| Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma | NCT01974284 | Papillary Thyro... | percutaneous et... | 18 Years - | Yale University | |
| Sutent Adjunctive Treatment of Differentiated Thyroid Cancer | NCT00668811 | Papillary Thyro... Follicular Thyr... Differentiated ... | SU011248, Suten... | 18 Years - | Medstar Health Research Institute | |
| Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer | NCT02442661 | Papillary Thyro... | 18 Years - | University of Colorado, Denver | ||
| A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | NCT00295763 | Differentiated ... | Thyrogen (thyro... | 18 Years - | Sanofi | |
| A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | NCT01100619 | Papillary Thyro... Follicular Thyr... Huerthle Cell T... Renal Cell Carc... | rosiglitazone XL184 | 18 Years - | Exelixis | |
| The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma | NCT06316895 | Papillary Thyro... | thyroid surgery ultrasound-guid... | 18 Years - 80 Years | Chinese PLA General Hospital | |
| CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer | NCT03359668 | Papillary Thyro... | Use of IV contr... | - | University Health Network, Toronto | |
| A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | NCT04731467 | Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden... | CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N... | 18 Years - | Purple Biotech Ltd. | |
| The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience | NCT04500925 | Well Differenti... Papillary Thyro... | UNILATERAL THYR... | 38 Years - 61 Years | Tel-Aviv Sourasky Medical Center | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation | NCT04129411 | Papillary Thyro... Papillary Thyro... | RFA | 18 Years - 85 Years | Mayo Clinic | |
| A Clinical Study of Transaxillary Endoscopic and Open Thyroidectomy for PTC | NCT05545852 | Papillary Thyro... | GTPET(Gasless T... COT(Conventiona... | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | NCT00295763 | Differentiated ... | Thyrogen (thyro... | 18 Years - | Sanofi | |
| Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale | NCT06286631 | Papillary Thyro... | 16 Years - 80 Years | Second Affiliated Hospital of Xi'an Jiaotong University | ||
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | NCT03630120 | Thyroid Cancer Thyroid Cancer,... Differentiated ... Papillary Thyro... Follicular Thyr... Poorly Differen... | Lenvatinib Sorafenib Cabozantinib Vandetanib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Papillary Thyroid Cancer and Central Lymp Node Dissection | NCT05873283 | Papillary Thyro... | 18 Years - 85 Years | Başakşehir Çam & Sakura City Hospital | ||
| Studies on Tumors of the Thyroid | NCT00001160 | Hurthle Cell Th... Tall Cell Varia... Follicular Thyr... Thyroid Cancer Papillary Thyro... | 68-Gallium Dota... | 6 Months - 98 Years | National Institutes of Health Clinical Center (CC) | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | NCT03906331 | Non Small Cell ... Medullary Thyro... Colon Cancer Breast Cancer Pancreatic Canc... Papillary Thyro... Other Solid Tum... | Selpercatinib | 18 Years - | Eli Lilly and Company | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Papillary Thyroid Cancer and Central Lymp Node Dissection | NCT05873283 | Papillary Thyro... | 18 Years - 85 Years | Başakşehir Çam & Sakura City Hospital | ||
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | NCT04544111 | Thyroid Cancer Thyroid Cancer,... Papillary Thyro... Follicular Thyr... Hurthle Cell Tu... Poorly Differen... Hurthle Cell Th... | Trametinib Dabrafenib PDR001 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | NCT05024929 | Papillary Thyro... Pediatric Cance... Differentiated ... | Whole body scan | 0 Years - | Children's Hospital of Philadelphia | |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | NCT05668962 | Thyroid Cancer Thyroid Carcino... Metastatic Thyr... Follicular Thyr... Unresectable Th... Papillary Thyro... | Selpercatinib Sodium Iodine I... rhTSH | 12 Years - | Massachusetts General Hospital | |
| The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma | NCT06316895 | Papillary Thyro... | thyroid surgery ultrasound-guid... | 18 Years - 80 Years | Chinese PLA General Hospital | |
| Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples | NCT06133374 | Papillary Thyro... | 18 Years - | University of Calgary | ||
| Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer | NCT02178345 | Papillary Thyro... | diffusion weigh... dynamic contras... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Prophylactic Central Neck Dissection for Papillary Thyroid Cancer | NCT01510002 | Papillary Thyro... | Total thyroidec... Total thyroidec... | 18 Years - | Jagiellonian University | |
| Radiofrequency Ablation of Papillary Thyroid Microcarcinoma | NCT05132205 | Papillary Thyro... | Radiofrequency ... | 18 Years - 100 Years | Johns Hopkins University | |
| CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer | NCT03359668 | Papillary Thyro... | Use of IV contr... | - | University Health Network, Toronto | |
| Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | NCT01709292 | Thyroid Cancer | Vemurafenib (Al... Vemurafenib (Po... Post Surgery - ... | 18 Years - | M.D. Anderson Cancer Center | |
| Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | NCT01709292 | Thyroid Cancer | Vemurafenib (Al... Vemurafenib (Po... Post Surgery - ... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY | NCT05766098 | Papillary Thyro... | Genotyping | - | Istituto Auxologico Italiano | |
| Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment | NCT01441154 | Malignant Strum... Papillary Thyro... Hurthle Cell Th... Follicular Thyr... Tall Cell Varia... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | NCT00295763 | Differentiated ... | Thyrogen (thyro... | 18 Years - | Sanofi | |
| Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy | NCT02140476 | Thyroid Goiter Papillary Thyro... | Bipolar vessel ... Conventional th... | 18 Years - 65 Years | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| Study of XL281 in Adults With Solid Tumors | NCT00451880 | Cancer Non-small-cell ... Colorectal Canc... Papillary Thyro... Melanoma | XL281 famotidine | 18 Years - | Exelixis | |
| Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma | NCT04664413 | Papillary Thyro... | 18 Years - | University of Salerno | ||
| Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid | NCT00984191 | Papillary Thyro... | 99mTc-MIBI SPEC... | 18 Years - | Chulalongkorn University | |
| Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY | NCT05766098 | Papillary Thyro... | Genotyping | - | Istituto Auxologico Italiano | |
| Targeted Therapy to Increase RAI Uptake in Metastatic DTC | NCT05024929 | Papillary Thyro... Pediatric Cance... Differentiated ... | Whole body scan | 0 Years - | Children's Hospital of Philadelphia | |
| More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated | NCT06439745 | Papillary Thyro... Papillary Carci... Thyroid Cancer Thyroid Carcino... Thyroid Cancer,... Lymph Node Meta... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | ||
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
